On November 17, 2015, the Forum for Collaborative HIV Research convened the 14th HCV Drug Development Advisory Group (DrAG) Meeting in San Francisco, CA, in conjunction with the 66th annual meeting of the American Association for the Study of Liver Diseases.*
At the 14th HCV DrAG Meeting, topics of discussion included:
- Resistance Data Updates
- State of the Art Summary from FDA Online Reviews
- A Clinician's Perspective on "What We Need to Know and What We Think We Know"
- Comparison of Different HCV Genotyping Platforms
- Forum Next Generation Sequencing Project
- Current and Upcoming Technologies for Resistance Testing
- Notes from the Field From Early Implementers of NS5A Resistance Testing and Treatment Considerations for Second-Line Therapy
Welcome and Updates - Veronica Miller, The Forum for Collaborative HIV Research
Session 1: Technologies That Support HCV Diagnosis and Treatment Management and New Data
Prevalence and Impact of Baseline NS5A RAVs on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1A Infection - Todd Black, Merck Research Laboratories
Prevalence of Pre-Treatment NS5A Resistance Associated Variants in Genotype 1 Patients Across Different Regions Using Deep Sequencing and Effect on Treatment Outcome with LDV/SOF - Jenny Svarovskaia, Gilead Sciences, Inc.
Session 2: The Role of NS5A Resistance Testing
Impact of HCV Polymorphisms in DAA Clinical Trials - Patrick Harrington, U.S. Food and Drug Administration
NS5A Resistance: What We Know and What We Think We Know - Jean-Michel Pawlotsky, University Hospital Henri Mondor
Evaluation of a Novel Platform for Determining Genotypes of HCV - Charles Cartwright, LabCorp
Forum NGS Project - Veronica Miller, The Forum for Collaborative HIV Research, and Chris Petropolous, Monogram Biosciences, Inc.
Current and Upcoming Technologies for Resistance Testing - Jacqueline Reeves, Monogram Biosciences, Inc.
Overview of Hepatitis C Virus Assays - Leen-Jan van Doorn, DDL Diagnostic Laboratory
Hepatitis C Resistance Testing at Quest Diagnostics - Ron Kagan, Quest Diagnostics
An Informal Study - Anita Howe, British Columbia Center for Excellence in HIV/AIDS
Will Detection of Pre-Existing (Baseline) NS5A RAVs with High-Fold In Vitro Resistance Be Another Predictor in Treatment Decision? - Johan Lennerstrand, Uppsala University
Next Steps & Thank You - Veronica Miller, The Forum for Collaborative HIV Research
*This is not an official function/event of the American Association for the Study of Liver Diseases.
